This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Grünenthal Spain.
Reference
Presal M, et al. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients. Clinical Rheumatology : 16 Aug 2019. Available from: URL: https://doi.org/10.1007/s10067-019-04739-3
Rights and permissions
About this article
Cite this article
Lesinurad + allopurinol more effective, less costly in Spain. PharmacoEcon Outcomes News 836, 16 (2019). https://doi.org/10.1007/s40274-019-6189-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6189-7